RenovaCare Inc.06.10.20
RenovaCare Inc., developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, has appointed its first chief medical officer, Jo Ellen Schweinle MD, former senior medical officer at the US Department of Health and Human Services; senior clinical director at Bayer Corporation, GlaxoSmithKline, McNeil Pharmaceuticals, Chiron/Novartis, and VP medical affairs at Axcan Pharma.
“We are privileged to have Dr. Schweinle join our executive leadership team as an accomplished physician, scientist and clinical investigator. She is a renowned medical voice and noted authority in the use of self-donated stem cells and burn therapies, cornerstones of our CellMist and SkinGun technologies for the isolation and spray of a patient’s own cells onto burns and wounds,” said Alan L. Rubino, RenovaCare CEO and president.
Schweinle, an award-winning physician-researcher, has led and managed numerous worldwide clinical studies. In her most recent role at U.S. Health and Human Services, Schweinle provided her clinical acumen towards the clinical development of a wide array of burn wound product candidates including therapeutics, debridement agents, and medical imaging devices.
"Dr. Schweinle, with whom I worked with for many years at BARDA, brings us over 30 years of medical, regulatory, and clinical trial expertise from global healthcare organizations and some of the world’s leading government and commercial teams. Her addition strengthens our clinical and regulatory programs for investigation into new and promising cell therapies using skin and other tissue sources and our patented CellMist System and SkinGun device,” explained, Dr. Robin A. Robinson, chief scientific officer for RenovaCare.
“We are privileged to have Dr. Schweinle join our executive leadership team as an accomplished physician, scientist and clinical investigator. She is a renowned medical voice and noted authority in the use of self-donated stem cells and burn therapies, cornerstones of our CellMist and SkinGun technologies for the isolation and spray of a patient’s own cells onto burns and wounds,” said Alan L. Rubino, RenovaCare CEO and president.
Schweinle, an award-winning physician-researcher, has led and managed numerous worldwide clinical studies. In her most recent role at U.S. Health and Human Services, Schweinle provided her clinical acumen towards the clinical development of a wide array of burn wound product candidates including therapeutics, debridement agents, and medical imaging devices.
"Dr. Schweinle, with whom I worked with for many years at BARDA, brings us over 30 years of medical, regulatory, and clinical trial expertise from global healthcare organizations and some of the world’s leading government and commercial teams. Her addition strengthens our clinical and regulatory programs for investigation into new and promising cell therapies using skin and other tissue sources and our patented CellMist System and SkinGun device,” explained, Dr. Robin A. Robinson, chief scientific officer for RenovaCare.